Pharma firms bet big on new B’desh law
|
|
Domestic other companies have lost the opportunity to sell cheap versions of patented medicines by the changes in patent laws in India three years ago, which are well in Bangladesh. Opportunities for technical partnerships, aufgehellt in Bangladesh, after changing their patent law in a bid to become a hub for the production of cheap copies of patented drugs. The World Trade Organization such drugs can be produced in the least developed countries by 2016. “This is an excellent way for Indian companies. 2005, a number of companies were concerned that his former business model focusing exclusively on the figure of ‘generics business can not function as well. however, given the fact that Bangladesh has a strong base Pharmaceuticals, could believe that the implementation of some of its operations, “Shamnad Basheer, scientific collaborator, the Oxford intellectual property (IP) Research Center, United Kingdom, said. After Bashir, the provisions relating to “parallel imports” of the Indian patent law allows the importation of drugs from each of these areas, if the exporter of products such patent is permitted under the law (in the country ) to produce, sell or distribute the product. In other words, drug trafficking in Bangladesh, the manufacturer could also open themselves to the market and India. Nazmul Ahsan, secretary-general, the Bangladesh Association of Pharmaceutical Industry (BAPI), agree with him. “Our government is actively working with various provisions, in order to maintain flexibility in the TRIPS agreement (Aspects of Intellectual Property Rights) under the Patent Law. It comes in the form of facilities, the production of medicines, patent protection is legally possible elsewhere. We can you spend other peoples, development, “he said. India, under the new patent regime is unable to provide raw materials or drugs in bulk of patented drugs. But there may be between products (this is a step in the manufacture of mass cycle of drugs) everywhere. If Indian companies to enhance the technological capabilities of its partners in Bangladesh, these intermediate products can be developed further into drug trafficking in bulk drugs and finished in this country. While these drugs have validated a market in all poor countries, but also countries like India, on the basis of compulsory licensing. Ahsan Bangladesh, the government has prepared a fleet of 300 hectares for the production of pharmaceutical drugs at average. “Many Indian companies have shown interest in a partnership with the incumbents in Bangladesh, bulk of other units in the park,” Ahsan said. Nityananda Reddy, managing director of Aurobindo Pharma and Senior Vice-President of Bulk Drugs Manufacturers of India (BDMA), will be emerging countries attractive option. “Indian bulk of other companies want to make good business as a supplier of raw materials prior to the other companies in bulk in Bangladesh. It is certainly attractive to all new products which are not in India,” he said. |